Breaking News

Abenza Upgrades Research & Development Capabilities in Cambridge

Invests in B cell discovery technologies and appoints Jamie Campbell as Vice President of Research & Development.

Author Image

By: Charlie Sternberg

Associate Editor

Abzena, a CDMO providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs), is upgrading its research and development capabilities in Cambridge, including an investment in B cell discovery technologies and the appointment of Jamie Campbell as Vice President of Research & Development. Investment in Primary B Cell Discovery Technologies As part of its investment in primary B cell antibody discovery technologies, Abzena has implemented the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters